Table 1.

Effect of β-TrCPΔF on growth of human breast cancer cells measured by the WST-1 assay

TreatmentT47D transductionMCF7 TransductionMDA-MB468 TransductionMCF10A Transduction
VectorβTrCPΔFVectorβTrCPΔFVectorβTrCPΔFVectorβTrCPΔF
DMSO1248 ± 76516 ± 19 *780 ± 49559 ± 39 2508 ± 711032 ± 34 *1515 ± 139649 ± 46 *
Doxorubicin
    1 nmol/LNTNTNTNTNTNT1215 ± 87416 ± 68
    1 μmol/LNTNTNTNT107 ± 816 ± 4 *NTNT
    5 μmol/L46 ± 617 ± 3 *217 ± 38133 ± 310 *NTNTNTNT
Tamoxifen
    5 μmol/L456 ± 99137 ± 19 *81 ± 1824 ± 3 *1844 ± 146257 ± 56 *NTNT
    15μmol/LNTNTNTNTNTNT1387 ± 250694 ± 108 *
Paclitaxel
    1 nmol/LNTNTNTNTNTNT1075 ± 73354 ± 46 *
    250 nmol/L532 ± 54217 ± 27 *538 ± 42363 ± 64 1175 ± 86170 ± 19 *NTNT
  • NOTE: Cell proliferation is measured by cell/WST1 reagent–generated absorbance at 450 nm minus the background (an absorbance of a tissue culture well containing medium without cells). Average data from three independent experiments (each in triplicate) ± SDs are shown.

    Abbreviation: NT, not tested.

  • * P < 0.01, compared with cells transduced with empty vector (Student's t test).

  • P < 0.05, compared with cells transduced with empty vector (Student's t test).